AAAAAA

   
Results: 1-25 | 26-30
Results: 1-25/30
Identification of polymorphisms in the 5 '-untranslated region of the TAFIgene: relationship with plasma TAFI levels and risk of venous thrombosis
Authors: Franco, RF Fagundes, MG Meijers, JCM Reitsma, PH Lourenco, D Morelli, V Maffei, FH Ferrari, IC Piccinato, CE Silva, WA Zago, MA
Citation: Rf. Franco et al., Identification of polymorphisms in the 5 '-untranslated region of the TAFIgene: relationship with plasma TAFI levels and risk of venous thrombosis, HAEMATOLOG, 86(5), 2001, pp. 510-517
The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration
Authors: Mosnier, LO Lisman, T van den Berg, HM Nieuwenhuis, HK Meijers, JCM Bouma, BN
Citation: Lo. Mosnier et al., The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration, THROMB HAEM, 86(4), 2001, pp. 1035-1039
C4b-binding protein inhibits the factor V-dependent but not the factor V-independent cofactor activity of protein S in the activated protein C-mediated inactivation of factor VIIIa
Authors: van de Poel, RHL Meijers, JCM Bouma, BN
Citation: Rhl. Van De Poel et al., C4b-binding protein inhibits the factor V-dependent but not the factor V-independent cofactor activity of protein S in the activated protein C-mediated inactivation of factor VIIIa, THROMB HAEM, 85(5), 2001, pp. 761-765
Regulation of fibrinolysis in plasma by TAFI and protein C is dependent onthe concentration of thrombomodulin
Authors: Mosnier, LO Meijers, JCM Bouma, BN
Citation: Lo. Mosnier et al., Regulation of fibrinolysis in plasma by TAFI and protein C is dependent onthe concentration of thrombomodulin, THROMB HAEM, 85(1), 2001, pp. 5-11
Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)
Authors: Bouma, BN Marx, PF Mosnier, LO Meijers, JCM
Citation: Bn. Bouma et al., Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U), THROMB RES, 101(5), 2001, pp. 329-354
Dimers of beta(2)-glycoprotein I mimic the in vitro effects of beta(2)-glycoprotein I-anti-beta(2)-glycoprotein I antibody complexes
Authors: Lutters, BCH Meijers, JCM Derksen, RHWM Arnout, J de Groot, PG
Citation: Bch. Lutters et al., Dimers of beta(2)-glycoprotein I mimic the in vitro effects of beta(2)-glycoprotein I-anti-beta(2)-glycoprotein I antibody complexes, J BIOL CHEM, 276(5), 2001, pp. 3060-3067
Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is notassociated with increased plasma fibrinolysis
Authors: Lisman, T Leebeek, FWG Mosnier, LO Bouma, BN Meijers, JCM Janssen, HLA Nieuwenhuis, HK De Groot, PG
Citation: T. Lisman et al., Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is notassociated with increased plasma fibrinolysis, GASTROENTY, 121(1), 2001, pp. 131-139
Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces
Authors: Simmelink, MJA Horbach, DA Derksen, RHWM Meijers, JCM Bevers, EM Willems, GM De Groot, PG
Citation: Mja. Simmelink et al., Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces, BR J HAEM, 113(3), 2001, pp. 621-629
Activation of coagulation factor XI, without detectable contact activationin dengue haemorrhagic fever
Authors: van Gorp, ECM Minnema, MC Suharti, C Mairuhu, ATA Brandjes, DPM ten Cate, H Hack, CE Meijers, JCM
Citation: Ecm. Van Gorp et al., Activation of coagulation factor XI, without detectable contact activationin dengue haemorrhagic fever, BR J HAEM, 113(1), 2001, pp. 94-99
Role of blood coagulation factor XI in downregulation of fibrinolysis
Authors: Bouma, BN Meijers, JCM
Citation: Bn. Bouma et Jcm. Meijers, Role of blood coagulation factor XI in downregulation of fibrinolysis, CURR OPIN H, 7(5), 2000, pp. 266-272
The interaction between anticoagulant protein S and complement regulatory C4b-binding protein (C4BP)
Authors: van de Poel, RHL Meijers, JCM Bouma, BN
Citation: Rhl. Van De Poel et al., The interaction between anticoagulant protein S and complement regulatory C4b-binding protein (C4BP), TREND CARD, 10(2), 2000, pp. 71-76
Binding of von Willebrand factor to collagen type III: Role of specific amino acids in the collagen binding domain of VWF and effects of neighboring domains
Authors: van der Plas, RM Gomes, L Marquart, JA Vink, T Meijers, JCM de Groot, PG Sixma, JJ Huizinga, EG
Citation: Rm. Van Der Plas et al., Binding of von Willebrand factor to collagen type III: Role of specific amino acids in the collagen binding domain of VWF and effects of neighboring domains, THROMB HAEM, 84(6), 2000, pp. 1005-1011
Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study
Authors: Middeldorp, S Meijers, JCM van den Ende, AE van Enk, A Bouma, BN Tans, G Rosing, J Prins, MH Buller, HR
Citation: S. Middeldorp et al., Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study, THROMB HAEM, 84(1), 2000, pp. 4-8
Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis - A randomized cross-over study of two low-dose oral contraceptives
Authors: Meijers, JCM Middeldorp, S Tekelenburg, W van den Ende, AE Tans, G Prins, MH Rosing, J Buller, HR Bouma, BN
Citation: Jcm. Meijers et al., Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis - A randomized cross-over study of two low-dose oral contraceptives, THROMB HAEM, 84(1), 2000, pp. 9-14
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways
Authors: Tans, G Curvers, J Middeldorp, S Thomassen, MCLGD Meijers, JCM Prins, MH Bouma, BN Buller, HR Rosing, J
Citation: G. Tans et al., A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways, THROMB HAEM, 84(1), 2000, pp. 15-21
Characterization of mouse thrombin-activatable fibrinolysis inhibitor
Authors: Marx, PF Wagenaar, GTM Reijerkerk, A Tiekstra, MJ van Rossum, AGSH Gebbink, MFBG Meijers, JCM
Citation: Pf. Marx et al., Characterization of mouse thrombin-activatable fibrinolysis inhibitor, THROMB HAEM, 83(2), 2000, pp. 297-303
Characterization of transgenic mice that secrete functional human protein C inhibitor into the circulation
Authors: Wagenaar, GTM van Vuuren, AJH Girma, M Tiekstra, MJ Kwast, L Koster, JG Rijneveld, AW Elisen, MGLM van der Poll, T Meijers, JCM
Citation: Gtm. Wagenaar et al., Characterization of transgenic mice that secrete functional human protein C inhibitor into the circulation, THROMB HAEM, 83(1), 2000, pp. 93-101
Coagulation factor XI and venous thrombosis - Reply
Authors: Meijers, JCM Rosendaal, FR
Citation: Jcm. Meijers et Fr. Rosendaal, Coagulation factor XI and venous thrombosis - Reply, N ENG J MED, 343(3), 2000, pp. 221-221
High levels of coagulation factor XI as a risk factor for venous thrombosis.
Authors: Meijers, JCM Tekelenburg, WLH Bouma, BN Bertina, RM Rosendaal, FR
Citation: Jcm. Meijers et al., High levels of coagulation factor XI as a risk factor for venous thrombosis., N ENG J MED, 342(10), 2000, pp. 696-701
Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage
Authors: Marx, PF Hackeng, TM Dawson, PE Griffin, JH Meijers, JCM Bouma, BN
Citation: Pf. Marx et al., Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage, J BIOL CHEM, 275(17), 2000, pp. 12410-12415
Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia
Authors: Meijers, JCM Oudijk, EJD Mosnier, LO Bos, R Bouma, BN Nieuwenhuis, HK Fijnheer, R
Citation: Jcm. Meijers et al., Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia, BR J HAEM, 108(3), 2000, pp. 518-523
Protein C inhibitor in platelets?
Authors: Meijers, JCM
Citation: Jcm. Meijers, Protein C inhibitor in platelets?, BLOOD, 95(5), 2000, pp. 1880-1881
C4b-binding protein protects coagulation factor Va from inactivation by activated protein C
Authors: van de Poel, RHL Meijers, JCM Rosing, J Tans, G Bouma, BN
Citation: Rhl. Van De Poel et al., C4b-binding protein protects coagulation factor Va from inactivation by activated protein C, BIOCHEM, 39(47), 2000, pp. 14543-14548
C4b-binding protein (C4BP) beta-chain short consensus repeat-2 specifically contributes to the interaction of C4BP with protein S
Authors: van de Poel, RHL Meijers, JCM Dahlback, B Bouma, BN
Citation: Rhl. Van De Poel et al., C4b-binding protein (C4BP) beta-chain short consensus repeat-2 specifically contributes to the interaction of C4BP with protein S, BL CELL M D, 25(17), 1999, pp. 279-286
Factor XI dependent and independent activation of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in plasma associated with clot formation
Authors: Bouma, BN Mosnier, LO Meijers, JCM Griffin, JH
Citation: Bn. Bouma et al., Factor XI dependent and independent activation of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in plasma associated with clot formation, THROMB HAEM, 82(6), 1999, pp. 1703-1708
Risultati: 1-25 | 26-30